Lovenox (enoxaparin) and Alcohol / Food Interactions
There are 2 alcohol/food/lifestyle interactions with Lovenox (enoxaparin) which include:
High Blood Pressure (Hypertension)
Severe Potential Hazard, High plausibility
heparin - active bleeding
The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation. Hemorrhage can occur at virtually any site in patients receiving heparin. An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event. Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion. Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration. In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy. There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery. For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring. Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.
- Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992): 119-29
- Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989): 401-4
- Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991): 2337-43
High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
anticoagulants - hypertension
Anticoagulants should be used with extreme caution in patients at increased risk for hemorrhage, including those patients with severe hypertension.
- "Product Information. Orgaran (danaparoid)." Organon, West Orange, NJ.
- "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Lovenox (enoxaparin)." Rhone-Poulenc Rorer, Collegeville, PA.
Lovenox (enoxaparin) drug Interactions
There are 275 drug interactions with Lovenox (enoxaparin)
Lovenox (enoxaparin) disease Interactions
There are 11 disease interactions with Lovenox (enoxaparin) which include:
- Liver Disease
- Peptic Ulcer Disease
- Subacute Bacterial Endocarditis
- Active Bleeding
- Renal Dysfunction
- Kidney Disease
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Do not stop taking any medications without consulting your healthcare provider.